Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype
about
Inhaled corticosteroids with combination inhaled long-acting beta 2 -agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary diseaseStudy Design and Outcomes of Korean Obstructive Lung Disease (KOLD) Cohort Study.Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?The bronchoscopic interventions for chronic obstructive pulmonary disease according to different phenotypes.Efficacy of bronchoscopic lung volume reduction by endobronchial valves in patients with heterogeneous emphysema: report on the first Asian casesPhenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene.Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary diseaseThree-month treatment response and exacerbation in chronic obstructive pulmonary disease.Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled TrialBronchoscopic lung volume reduction by endobronchial valve in advanced emphysema: the first Asian report.IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.COPD: it is time to change!Role of Chitinase 3-Like-1 in Interleukin-18-Induced Pulmonary Type 1, Type 2, and Type 17 Inflammation; Alveolar Destruction; and Airway Fibrosis in the Murine Lung.A challenge to the seven widely believed concepts of COPD.Chronic obstructive pulmonary disease: lobe-based visual assessment of volumetric CT by Using standard images--comparison with quantitative CT and pulmonary function test in the COPDGene study.Resolvin D1 prevents smoking-induced emphysema and promotes lung tissue regenerationEfficacy and Safety of Roflumilast in Korean Patients with COPD.Defining phenotypes in COPD: an aid to personalized healthcare.The asthma COPD overlap syndrome (ACOS).Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.Oxidation pathway and exacerbations in COPD: the role of NAC.Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go?Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome.Abrupt withdrawal of inhaled corticosteroids does not result in spirometric deterioration in chronic obstructive pulmonary disease: Effect of phenotyping?Re: prevalence of chronic obstructive pulmonary disease among smokers attending primary healthcare clinics in Saudi Arabia.A cluster analysis of chronic obstructive pulmonary disease in dusty areas cohort identified three subgroups.CT densitometry in emphysema: a systematic review of its clinical utility.Can computed tomography and carbon monoxide transfer coefficient diagnose an asthma-like phenotype in COPD?Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.Bronchoscopic bullectomy with a one-way endobronchial valve to treat a giant bulla in an emphysematic lung: a case report.A novel CT-emphysema index/FEV approach of phenotyping COPD to predict mortalityBlood eosinophil count as a prognostic biomarker in COPD
P2860
Q24186966-950E3320-FAE2-4C30-8F33-A3CBB8BB8C14Q33612354-D2C7D776-7D15-40C4-9139-A211FBD54FA6Q33742510-98752533-C8F7-4685-AF3C-99E694284D39Q33780283-BFE7B307-3695-451A-8357-E78449E9A423Q34429562-F255830A-5097-4072-9B05-692BC6A15D70Q34619853-6D50FDD0-5839-4AAE-A834-69523CAB80EFQ34634754-0B10E4A1-1520-47FD-AD5F-95ABA877EA11Q34779478-0079CE6E-C855-4314-8846-807988260FB7Q35675040-CDAA46A4-8B66-4A62-96D2-4B4CCB99C962Q35867300-359DCB35-57EC-40ED-8289-56CC95673173Q35914790-58D55EAE-ABB8-4E1B-926A-EBD96B1A106CQ36026286-2F0AAD0E-FC60-44CF-BE73-A0FBFFB2638DQ36188224-1164CE63-FAA3-4A3A-9B48-2477811A2E59Q36288971-1FF479E3-E844-423A-A54A-389B9F026D18Q36549088-714F25AA-8147-41AD-A1D2-4C117399D731Q36558218-DF153D14-D5F8-436F-8661-56F404EB3DD9Q36573397-F887DE75-5E23-46E9-8AAB-53F51AB72EADQ36961495-D498CA79-FB11-4680-9AB0-235C15A2E19DQ37110198-9060D2C1-7071-4E82-B31E-ADB2EEE9DBD8Q38208244-CB8A502F-5C73-4496-9517-C3F6CF5B6AB0Q38364870-4777972B-EAFB-4092-A592-F946522AA0CEQ38586322-F319DC18-825A-4B9A-B13D-776C9723A320Q38633304-0234A3D0-CD06-41E6-8958-C46B7F3D1E92Q39461476-CEE0DD6B-65BA-44E8-8283-2876E9AC0219Q40136175-25683D44-03F1-4946-8673-E9FDD1519F12Q42007380-528A9EA3-04B5-4473-AC35-C715235E6F2DQ42868497-0A113274-89D3-4366-9F16-1F78A2055CBBQ47170520-824EB62C-93EC-4903-8D82-044B8B218FC1Q49781350-F8F9932F-66B9-4492-9161-8F59AEB98A90Q50197250-E62EF3DA-3056-4398-8D64-4BCE6BE07D7EQ51599981-9E4EAE29-D469-45C6-A518-1955C1B03DBFQ51674306-6F5756FF-F2C0-411A-9B1D-897A76E4453FQ58137679-5C65CB49-C4BC-48BF-A1DD-B064EA59567DQ59125886-0B27E0AB-DA99-46C3-9DEA-8F9511EA5DDB
P2860
Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2010
@uk
name
Responses to inhaled long-acti ...... roid according to COPD subtype
@en
Responses to inhaled long-acti ...... roid according to COPD subtype
@nl
type
label
Responses to inhaled long-acti ...... roid according to COPD subtype
@en
Responses to inhaled long-acti ...... roid according to COPD subtype
@nl
prefLabel
Responses to inhaled long-acti ...... roid according to COPD subtype
@en
Responses to inhaled long-acti ...... roid according to COPD subtype
@nl
P2093
P1433
P1476
Responses to inhaled long-acti ...... roid according to COPD subtype
@en
P2093
Eun-Kyung Kim
Ho Il Yoon
Ji-Hyun Lee
Jin Won Huh
Joon Beom Seo
Sang Do Lee
Sang-Min Lee
Sangyeub Lee
Seong Yong Lim
Seung Soo Sheen
P304
P356
10.1016/J.RMED.2009.10.024
P577
2010-04-01T00:00:00Z